The role of in vivo molecular imaging with PET and SPECT in the elucidation of psychiatric drug action and new drug development

European Neuropsychopharmacology

Volumn 12, Issue 6, 2002, Pages 503-511

  Talbot, Peter S ^a   Laruelle, Marc ^a,b  

^a New York State Psychiatric Institute ^*  (United States)

^b NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

Author keywords

Molecular imaging; Positron emission tomography; Single photon emission computed tomography

Indexed keywords

ANTIDEPRESSANT AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; BENZAMIDE; BENZODIAZEPINE DERIVATIVE; BUTYROPHENONE; CITALOPRAM; CLONAZEPAM; CLOZAPINE; DOPAMINE 2 RECEPTOR BLOCKING AGENT; FLUMAZENIL; FLUPENTIXOL; HALOPERIDOL; METHYLPHENIDATE; MUSCARINIC RECEPTOR BLOCKING AGENT; NEUROLEPTIC AGENT; NEW DRUG; OLANZAPINE; PAROXETINE; PINDOLOL; QUETIAPINE; RACLOPRIDE; RISPERIDONE; SEROTONIN 1A AGONIST; SEROTONIN 2A ANTAGONIST; SEROTONIN UPTAKE INHIBITOR; SERTINDOLE; TRACER; UNINDEXED DRUG; ZIPRASIDONE; ZOTEPINE;

ATTENTION DEFICIT DISORDER; BINDING AFFINITY; BRAIN REGION; CLINICAL TRIAL; COCAINE DEPENDENCE; DISEASE SEVERITY; DISSOCIATION; DOPAMINE BRAIN LEVEL; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG RETENTION; DRUG SELECTIVITY; EXTRAPYRAMIDAL SYMPTOM; HUMAN; IMAGING SYSTEM; IN VIVO STUDY; ISOTOPE LABELING; LIMBIC SYSTEM; MENTAL DISEASE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RECEPTOR AFFINITY; RECEPTOR OCCUPANCY; RELIABILITY; REVIEW; SCHIZOPHRENIA; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

EID: 0036895218     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-977X(02)00099-8     Document Type: Article

References (78)

1. Abadie P., Rioux P., Scatton B., Zarifian E., Barre L., Patat A., Baron J.C. Central benzodiazepine receptor occupancy by zolpidem in the human brain as assessed by positron emission tomography. Eur. J. Pharmacol. 295:1996;35-44.
2. Abi-Dargham A., Hwang D.R., Huang Y., Zea-Ponce Y., Martinez D., Lombardo I., Broft A., Hashimoto T., Slifstein M., Mawlawi O., Van Heertum R., Laruelle M. Reliable quantification of both striatal and extrastriatal D2 receptors in humans with [18F]fallypride. J. Nucl. Med. 41:2000;139P.
3. Abi-Dargham A., Rodenhiser J., Printz D., Zea-Ponce Y., Gil R., Kegeles L., Weiss R., Cooper T., Mann J.J., Van Heertum R., Gorman J., Laruelle M. Increased baseline occupancy of D2 receptors by dopamine in schizophrenia. Proc. Natl. Acad. Sci. USA. 97:2000;8104-8109.
4. Andree B., Thorberg S.O., Halldin C., Farde L. Pindolol binding to 5-HT1A receptors in the human brain confirmed with positron emission tomography. Psychopharmacology (Berl.). 144:1999;303-305.
5. Artigas F., Celada P., Laruelle M., Adell A. How does pindolol improve antidepressant action? Trends. Pharmacol. Sci. 22:2001;224-228.
6. Barnas C., Quiner S., Tauscher J., Hilger E., Willeit M., Kufferle B., Asenbaum S., Brucke T., Rao M.L., Kasper S. In vivo (123)I IBZM SPECT imaging of striatal dopamine 2 receptor occupancy in schizophrenic patients. Psychopharmacologia. 157:2001;236-242.
7. Bench C.J., Lammertsma A.A., Grasby P.M., Dolan R.J., Warrington S.J., Boyce M., Gunn K.P., Brannick L.Y., Frackowiak R.S.J. The time course of binding to striatal dopamine D2 receptors by the neuroleptic ziprasidone (CP-88,059-01) determined by positron emission tomography. Psychopharmacology (Berl.). 124:1996;141-147.
8. Bernardo M., Parellada E., Lomena F., Catafau A.M., Font M., Gomez J.C., Lopez-Carrero C., Gutierrez F., Pavia J., Salamero M. Double-blind olanzapine vs. haloperidol D2 dopamine receptor blockade in schizophrenic patients: a baseline-endpoint. Psychiatry Res. 107:2001;87-97.
9. Bigliani V., Mulligan R.S., Acton P.D., Ohlsen R.I., Pike V.W., Ell P.J., Gacinovic S., Kerwin R.W., Pilowsky L.S. Striatal and temporal cortical D2/D3 receptor occupancy by olanzapine and sertindole in vivo: a [123I]epidepride single photon emission tomography (SPET) study. Psychopharmacologia. 150:2000;132-140.
10. Bigliani V., Mulligan R.S., Acton P.D., Visvikis D., Ell P.J., Stephenson C., Kerwin R.W., Pilowsky L.S. In vivo occupancy of striatal and temporal cortical D2/D3 dopamine receptors by typical antipsychotic drugs. [123I]Epidepride single photon emission tomography (SPET) study. Br. J. Psychiatry. 175:1999;231-238.
11. Blier P., de Montigny C. Possible serotonergic mechanisms underlying the antidepressant and anti-obsessive-compulsive disorder responses. Biol. Psychiatry. 44:1998;313-323.
12. Busatto G.F., Pilowsky L.S., Costa D.C., Ell P.J., Verhoeff N.P., Kerwin R.W. Dopamine D2 receptor blockade in vivo with the novel antipsychotics risperidone and remoxipride - an 123I-IBZM single photon emission tomography (SPET) study. Psychopharmacologia. 117:1995;55-61.
13. Deutch A.Y., Lee M.C., Iadarola M.J. Regionally specific effects of atypical antipsychotic drugs on striatal fos expression: the nucleus accumbens shell as a locus of antipsychotic action. Mol. Cell. Neurosci. 3:1992;332-341.
14. Dougherty D.D., Alpert N.M., Rauch S.L., Fischman A.J. In vivo neuroreceptor imaging techniques in psychiatric drug development. Rauch S.L. Psychiatric Neuroimaging Research: Contemporary Strategies. 2001;193-205 American Psychiatric Publishing, Washington, DC.
15. Drevets W.C., Gautier C., Price J.C., Kupfer D.J., Kinahan P.E., Grace A.A., Price J.L., Mathis C.A. Amphetamine-induced dopamine release in human ventral striatum correlates with euphoria. Biol. Psychiatry. 49:2001;81-96.
16. Farde L., Nordstrom A.L., Nyberg S., Halldin C., Sedvall G. D1-, D2-, and 5-HT2-receptor occupancy in clozapine-treated patients. J. Clin. Psychiatry. 55:1994;67-69.
17. Farde L., Nordstrom A.L., Wiesel F.A., Pauli S., Halldin C., Sedvall G. Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. Arch. Gen. Psychiatry. 49:1992;538-544.
18. Farde L., Nyberg S., Oxenstierna G., Nakashima Y., Halldin C., Ericsson B. Positron emission tomography studies on D2 and 5-HT2 receptor binding in risperidone-treated schizophrenic patients. J. Clin. Psychopharmacol. 15:1995;19S-23S.
19. Farde L., Suhara T., Nyberg S., Karlsson P., Nakashima Y., Hietala J., Halldin C. A PET study of [C-11]FLB 457 binding to extrastriatal D-2-dopamine receptors in healthy subjects and antipsychotic drug-treated patients. Psychopharmacology (Berl.). 133:1997;396-404.
20. Fitzgerald P.B., Kapur S., Remington G., Roy P., Zipursky R.B. Predicting haloperidol occupancy of central dopamine D2 receptors from plasma levels. Psychopharmacology (Berl.). 149:2000;1-5.
21. Fujita M., Woods S.W., Verhoeff N.P., Abi-Dargham A., Baldwin R.M., Zoghbi S.S., Soares J.C., Jatlow P.A., Krystal J.H., Rajeevan N., Charney D.S., Seibyl J.P., Innis R.B. Changes of benzodiazepine receptors during chronic benzodiazepine administration in humans. Eur. J. Pharmacol. 368:1999;161-172.
22. Fuyita M., Innis R.B. In vivo molecular imaging: ligand development and research applications. Nemeroff C. Neuropsychopharmacology, The Fifth Generation of Progress. 2002;411-425 Lippincott, Williams & Wilkins, Philadelphia.
23. Gatley S.J., Volkow N.D., Gifford A.N., Ding Y.S., Logan J., Wang G.J. Model for estimating dopamine transporter occupancy and subsequent increases in synaptic dopamine using positron emission tomography and carbon-11-labeled cocaine. Biochem. Pharmacol. 53:1997;43-52.
24. Gatley S.J., Volkow N.D., Gifford A.N., Fowler J.S., Dewey S.L., Ding Y.S., Logan J. Dopamine-transporter occupancy after intravenous doses of cocaine and methylphenidate in mice and humans. Psychopharmacologia. 146:1999;93-100.
25. Gefvert O., Bergstrom M., Langstrom B., Lundberg T., Lindstrom L., Yates R. Time course of central nervous dopamine-D2 and 5-HT2 receptor blockade and plasma drug concentrations after discontinuation of quetiapine (Seroquel) in patients with schizophrenia. Psychopharmacologia. 135:1998;119-126.
26. Gefvert O., Lundberg T., Wieselgren I.M., Bergstrom M., Langstrom B., Wiesel F., Lindstrom L. D(2) and 5HT(2A) receptor occupancy of different doses of quetiapine in schizophrenia: a PET study. Eur. Neuropsychopharmacol. 11:2001;105-110.
27. Hagberg G., Gefvert O., Bergstrom M., Wieselgren I.M., Lindstrom L., Wiesel F.A., Langstrom B. N-[11C]Methylspiperone PET, in contrast to [11C]raclopride, fails to detect D2 receptor occupancy by an atypical neuroleptic. Psychiatry Res. 82:1998;147-160.
28. Halldin C., Gulyas B., Langer O., Farde L. Brain radioligands - state of the art and new trends. Q. J. Nucl. Med. 45:2001;139-152.
29. Kapur S., Remington G., Zipursky R.B., Wilson A.A., Houle S. The D2 dopamine receptor occupancy of risperidone and its relationship to extrapyramidal symptoms: a PET study. Life Sci. 57:1995;PL103-PL107.
30. Kapur S., Seeman P. Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: a new hypothesis. Am. J. Psychiatry. 158:2001;360-369.
31. Kapur S., Zipursky R., Jones C., Remington G., Houle S. Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am. J. Psychiatry. 157:2000;514-520.
32. Kapur S., Zipursky R., Jones C., Shammi C.S., Remington G., Seeman P. A positron emission tomography study of quetiapine in schizophrenia: a preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy. Arch. Gen. Psychiatry. 57:2000;553-559.
33. Kapur S., Zipursky R.B., Remington G. Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. Am. J. Psychiatry. 156:1999;286-293.
34. Kapur S., Zipursky R.B., Remington G., Jones C., DaSilva J., Wilson A.A., Houle S. 5-HT2 and D2 receptor occupancy of olanzapine in schizophrenia: a PET investigation. Am. J. Psychiatry. 155:1998;921-928.
35. Kasper S., Tauscher J., Kufferle B., Barnas C., Hesselmann B., Asenbaum S., Podreka I., Brucke T. Sertindole and dopamine D2 receptor occupancy in comparison to risperidone, clozapine and haloperidol - a 123I-IBZM SPECT study. Psychopharmacologia. 136:1998;367-373.
36. Kent J.M., Coplan J.D., Lombardo I., Parsey R.V., Hwang D.R., Simpson N., Mawlawi O., Anderson A., Mann J.J., Van Heertum R., Gorman J.M., Laruelle M. Imaging the serotonin transporter in social phobia with (+)[C-11]McN5652. J. Nucl. Med. 41:2000;200P.
37. Knable M.B., Heinz A., Raedler T., Weinberger D.R. Extrapyramidal side effects with risperidone and haloperidol at comparable D2 receptor occupancy levels. Psychiatry Res. 75:1997;91-101.
38. Kufferle B., Tauscher J., Asenbaum S., Vesely C., Podreka I., Brucke T., Kasper S. IBZM SPECT imaging of striatal dopamine-2 receptors in psychotic patients treated with the novel antipsychotic substance quetiapine in comparison to clozapine and haloperidol. Psychopharmacologia. 133:1997;323-328.
39. Lavalaye J., Booij J., Linszen D.H., Reneman L., van Royen E.A. Higher occupancy of muscarinic receptors by olanzapine than risperidone in patients with schizophrenia. A[123I]-IDEX SPECT study. Psychopharmacologia. 156:2001;53-57.
40. Lavalaye J., Linszen D.H., Booij J., Reneman L., Gersons B.P., van Royen E.A. Dopamine D2 receptor occupancy by olanzapine or risperidone in young patients with schizophrenia. Psychiatry Res. 92:1999;33-44.
41. Malizia A.L., Gunn R.N., Wilson S.J., Waters S.H., Bloomfield P.M., Cunningham V.J., Nutt D.J. Benzodiazepine site pharmacokinetic/pharmacodynamic quantification in man: direct measurement of drug occupancy and effects on the human brain in vivo. Neuropharmacology. 35:1996;1483-1491.
42. Martinez D., Broft A., Laruelle M. Pindolol augmentation of antidepressant treatment: recent contributions from brain imaging studies. Biol. Psychiatry. 48:2000;844-853.
43. Martinez D., Hwang D., Mawlawi O., Slifstein M., Kent J., Simpson N., Parsey R.V., Hashimoto T., Huang Y., Shinn A., Van Heertum R., Abi-Dargham A., Caltabiano S., Malizia A., Cowley H., Mann J.J., Laruelle M. Differential occupancy of somatodendritic and postsynaptic 5HT(1A) receptors by pindolol. A dose-occupancy study with [11C]WAY 100635 and positron emission tomography in humans. Neuropsychopharmacology. 24:2001;209-229.
44. Mawlawi O., Martinez D., Slifstein M., Broft A., Chatterjee R., Hwang D.R., Huang Y., Simpson N., Ngo K., Van Heertum R., Laruelle M. Imaging human mesolimbic dopamine transmission with positron emission tomography: I. Accuracy and precision of D2 receptor parameter measurements in ventral striatum. J. Cereb. Blood Flow Metab. 21:2001;1034-1057.
45. Meisenzahl E.M., Dresel S., Frodl T., Schmitt G.J., Preuss U.W., Rossmuller B., Tatsch K., Mager T., Hahn K., Moller H.J. D2 receptor occupancy under recommended and high doses of olanzapine: an iodine-123-iodobenzamide SPECT study. J. Psychopharmacol. 14:2000;364-370.
46. Meyer J.H., Wilson A.A., Ginovart N., Goulding V., Hussey D., Hood K., Houle S. Occupancy of serotonin transporters by paroxetine and citalopram during treatment of depression: a [(11)C]DASB PET imaging study. Am. J. Psychiatry. 158:2001;1843-1849.
47. Mukherjee J., Christian B.T., Narayanan T.K., Shi B., Mantil J. Measurement of striatal and extrastriatal D-2 receptor occupancy by clozapine and risperidone using [18F]fallypride and PET. Neuroimage. 11:2000;S53.
48. Nordstrom A.L., Farde L., Nyberg S., Karlsson P., Halldin C., Sedvall G. D1, D2, and 5-HT2 receptor occupancy in relation to clozapine serum concentration: a PET study of schizophrenic patients. Am. J. Psychiatry. 152:1995;1444-1449.
49. Nordstrom A.L., Farde L., Wiesel F.A., Forslund K., Pauli S., Halldin C., Uppfeldt G. Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: a double-blind PET study of schizophrenic patients. Biol. Psychiatry. 33:1993;227-235.
50. Nordstrom A.L., Nyberg S., Olsson H., Farde L. Positron emission tomography finding of a high striatal D2 receptor occupancy in olanzapine-treated patients. Arch. Gen. Psychiatry. 55:1998;283-284.
51. Nyberg S., Eriksson B., Oxenstierna G., Halldin C., Farde L. Suggested minimal effective dose of risperidone based on PET-measured D2 and 5-HT2A receptor occupancy in schizophrenic patients. Am. J. Psychiatry. 156:1999;869-875.
52. Nyberg S., Farde L., Eriksson L., Halldin C., Eriksson B. 5-HT2 and D2 dopamine receptor occupancy in the living human brain. A PET study with risperidone. Psychopharmacology (Berl.). 110:1993;265-672.
53. Nyberg S., Nilsson U., Okubo Y., Halldin C., Farde L. Implications of brain imaging for the management of schizophrenia. Int. Clin. Psychopharmacol. 13:1998;S15-S20.
54. Olsson H., Farde L. Potentials and pitfalls using high affinity radioligands in pet and spet determinations on regional drug induced d2 receptor occupancy - a simulation study based on experimental data. Neuroimage. 14:2001;936-945.
55. Pilowsky L.S. Probing targets for antipsychotic drug action with PET and SPET receptor imaging. Nucl. Med. Commun. 22:2001;829-833.
56. Pilowsky L.S., Busatto G.F., Taylor M., Costa D.C., Sharma T., Sigmundsson T., Ell P.J., Nohria V., Kerwin R.W. Dopamine D2 receptor occupancy in vivo by the novel atypical antipsychotic olanzapine - a 123I IBZM single photon emission tomography (SPET) study. Psychopharmacologia. 124:1996;148-153.
57. Pilowsky L.S., Costa D.C., Ell P.J., Murray R.M., Verhoeff N.P., Kerwin R.W. Clozapine, single photon emission tomography, and the D2 dopamine receptor blockade hypothesis of schizophrenia. Lancet. 340:1992;199-202.
58. Pilowsky L.S., Mulligan R.S., Acton P.D., Ell P.J., Costa D.C., Kerwin R.W. Limbic selectivity of clozapine. Lancet. 350:1997;490-491.
59. Pilowsky L.S., O'Connell P., Davies N., Busatto G.F., Costa D.C., Murray R.M., Ell P.J., Kerwin R.W. In vivo effects on striatal dopamine D2 receptor binding by the novel atypical antipsychotic drug sertindole - a 123I IBZM single photon emission tomography (SPET) study. Psychopharmacologia. 130:1997;152-158.
60. Pirker W., Asenbaum S., Kasper S., Walter H., Angelberger P., Koch G., Pozzera A., Deecke L., Podreka I., Brucke T. beta-CIT SPECT demonstrates blockade of 5HT-uptake sites by citalopram in the human brain in vivo. J. Neural Transm. Genet. Sect. 100:1995;247-256.
61. Rabiner E.A., Bhagwagar Z., Gunn R.N., Sargent P.A., Bench C.J., Cowen P.J., Grasby P.M. Pindolol augmentation of selective serotonin reuptake inhibitors: PET evidence that the dose used in clinical trials is too low. Am. J. Psychiatry. 158:2001;2080-2082.
62. Rabiner E.A., Gunn R.N., Castro M.E., Sargent P.A., Cowen P.J., Koepp M.J., Meyer J.H., Bench C.J., Harrison P.J., Pazos A., Sharp T., Grasby P.M. Beta-blocker binding to human 5-HT(1A) receptors in vivo and in vitro: implications for antidepressant therapy. Neuropsychopharmacology. 23:2000;285-293.
63. Raedler T.J., Knable M.B., Jones D.W., Lafargue T., Urbina R.A., Egan M.F., Pickar D., Weinberger D.R. In vivo olanzapine occupancy of muscarinic acetylcholine receptors in patients with schizophrenia. Neuropsychopharmacology. 23:2000;56-68.
64. Raedler T.J., Knable M.B., Lafargue T., Urbina R.A., Egan M.F., Pickar D., Weinberger D.R. In vivo determination of striatal dopamine D2 receptor occupancy in patients treated with olanzapine. Psychiatry Res. 90:1999;81-90.
65. Robertson G.S., Matsumura H., Fibiger H.C. Induction patterns of Fos-like immunoreactivity in the forebrain as predictors of atypical antipsychotic activity. J. Pharmacol. Exp. Ther. 271:1994;1058-1066.
66. Schlaepfer T.E., Pearlson G.D., Wong D.F., Marenco S., Dannals R.F. PET study of competition between intravenous cocaine and [11C]raclopride at dopamine receptors in human subjects. Am. J. Psychiatry. 154:1997;1209-1213.
67. Shinotoh H., Iyo M., Yamada T., Inoue O., Suzuki K., Itoh T., Fukuda H., Yamasaki T., Tateno Y., Hirayama K. Detection of benzodiazepine receptor occupancy in the human brain by positron emission tomography. Psychopharmacologia. 99:1989;202-207.
68. Stephenson C.M., Bigliani V., Jones H.M., Mulligan R.S., Acton P.D., Visvikis D., Ell P.J., Kerwin R.W., Pilowsky L.S. Striatal and extra-striatal D(2)/D(3) dopamine receptor occupancy by quetiapine in vivo. Br. J. Psychiatry. 177:2000;408-415.
69. 123I]Iomazenil SPECT imaging demonstrates significant benzodiazepine receptor reserve in human and nonhuman primate brain. Neuropharmacology. 32:1993;671-680.
70. Talvik M., Nordstrom A.L., Nyberg S., Olsson H., Halldin C., Farde L. No support for regional selectivity in clozapine-treated patients: a PET study with [(11)C]raclopride and [(11)C]FLB 457. Am. J. Psychiatry. 158:2001;926-930.
71. Tauscher J., Kapur S. Choosing the right dose of antipsychotics in schizophrenia: lessons from neuroimaging studies. CNS Drugs. 15:2001;671-678.
72. Tauscher J., Kufferle B., Asenbaum S., Fischer P., Pezawas L., Barnas C., Tauscher-Wisniewski S., Brucke T., Kasper S. In vivo 123I IBZM SPECT imaging of striatal dopamine-2 receptor occupancy in schizophrenic patients treated with olanzapine in comparison to clozapine and haloperidol. Psychopharmacologia. 141:1999;175-181.
73. Tsukada H., Harada N., Ohba H., Nishiyama S., Kakiuchi T. Facilitation of dopaminergic neural transmission does not affect [(11)C]SCH23390 binding to the striatal D(1) dopamine receptors, but the facilitation enhances phosphodiesterase type-IV activity through D(1) receptors: PET studies in the conscious monkey brain. Synapse. 42:2001;258-265.
74. Volkow N.D., Wang G.J., Fowler J.S., Gatley S.J., Logan J., Ding Y.S., Hitzemann R., Pappas N. Dopamine transporter occupancies in the human brain induced by therapeutic doses of oral methylphenidate. Am. J. Psychiatry. 155:1998;1325-1331.
75. Volkow N.D., Wang G.J., Fowler J.S., Logan J., Franceschi D., Maynard L., Ding Y.S., Gatley S.J., Gifford A., Zhu W., Swanson J.M. Relationship between blockade of dopamine transporters by oral methylphenidate and the increases in extracellular dopamine: therapeutic implications. Synapse. 43:2002;181-187.
76. Volkow N.D., Wang G.J., Fowler J.S., Logan J., Gerasimov M., Maynard L., Ding Y.S., Gatley S.J., Gifford A., Franceschi D. Therapeutic doses of oral methylphenidate significantly increase extracellular dopamine in the human brain. J. Neurosci. 21:2001;RC121.
77. Wolkin A., Barouche F., Wolf A.P., Rotrosen J., Fowler J.S., Shiue C.Y., Cooper T.B., Brodie J.D. Dopamine blockade and clinical response: evidence for two biological subgroups of schizophrenia. Am. J. Psychiatry. 146:1989;905-908.
78. Wolkin A., Brodie J.D., Barouche F., Rotrosen J., Wolf A.P., Smith M., Fowler J., Cooper T.B. Dopamine receptor occupancy and plasma haloperidol levels. Arch. Gen. Psychiatry. 46:1989;482-484.